165 related articles for article (PubMed ID: 20167924)
1. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
Ding H; Wu B; Wang H; Lu Z; Yan J; Wang X; Shaffer JR; Hui R; Wang DW
Circ Res; 2010 Apr; 106(6):1145-52. PubMed ID: 20167924
[TBL] [Abstract][Full Text] [Related]
2. Down but not out: candidate gene-based studies still have value in a world dominated by whole genome approaches.
Sharma P; Bentley P
Circ Res; 2010 Apr; 106(6):1019-21. PubMed ID: 20360264
[No Abstract] [Full Text] [Related]
3. DDAH1 promoter -396 4N insertion variant is associated with increased risk of type 2 diabetes in a gender-dependent manner.
Zhu F; Zhou C; Wen Z; Wang DW
Mol Genet Genomic Med; 2020 Jan; 8(1):e1011. PubMed ID: 31733101
[TBL] [Abstract][Full Text] [Related]
4. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study.
Lu TM; Lin SJ; Lin MW; Hsu CP; Chung MY
Cardiovasc Diabetol; 2011 Feb; 10():16. PubMed ID: 21303562
[TBL] [Abstract][Full Text] [Related]
5. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
[TBL] [Abstract][Full Text] [Related]
6. AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
Amir M; Hassanein SI; Abdel Rahman MF; Gad MZ
Mol Biol Rep; 2018 Dec; 45(6):2411-2419. PubMed ID: 30284143
[TBL] [Abstract][Full Text] [Related]
7. DDAH1 and DDAH2 polymorphisms associate with asymmetrical dimethylarginine plasma levels in erectile dysfunction patients but not in healthy controls.
Brites-Anselmi G; Azevedo AMM; Miyazaki AHL; Pinheiro LC; Coeli-Lacchini FB; de Andrade MF; Molina CAF; Tucci S; Hirsch E; Tanus-Santos JE; Lacchini R
Nitric Oxide; 2019 Nov; 92():11-17. PubMed ID: 31394201
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in the dimethylarginine dimethylaminohydrolase 1 gene (DDAH1) is related to asymmetric dimethylarginine (ADMA) levels, but not to endothelium-dependent vasodilation.
Lind L; Ingelsson E; Kumar J; Syvänen AC; Axelsson T; Teerlink T
Vasc Med; 2013 Aug; 18(4):192-9. PubMed ID: 23892448
[TBL] [Abstract][Full Text] [Related]
10. The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: Relation with endothelial ADMA levels.
Guo YJ; Chen L; Bai YP; Li L; Sun J; Zhang GG; Yang TL; Xia J; Li YJ; Chen XP
Atherosclerosis; 2010 Aug; 211(2):545-50. PubMed ID: 20417517
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.
Lüneburg N; Lieb W; Zeller T; Chen MH; Maas R; Carter AM; Xanthakis V; Glazer NL; Schwedhelm E; Seshadri S; Ikram MA; Longstreth WT; Fornage M; König IR; Loley C; Ojeda FM; Schillert A; Wang TJ; Sticht H; Kittel A; König J; Benjamin EJ; Sullivan LM; Bernges I; Anderssohn M; Ziegler A; Gieger C; Illig T; Meisinger C; Wichmann HE; Wild PS; Schunkert H; Psaty BM; Wiggins KL; Heckbert SR; Smith N; Lackner K; Lunetta KL; Blankenberg S; Erdmann J; Munzel T; Grant PJ; Vasan RS; Böger RH
Circ Cardiovasc Genet; 2014 Dec; 7(6):864-72. PubMed ID: 25245031
[TBL] [Abstract][Full Text] [Related]
12. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.
Zhang P; Hu X; Xu X; Chen Y; Bache RJ
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):890-7. PubMed ID: 21212404
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.
Ivashchenko CY; Bradley BT; Ao Z; Leiper J; Vallance P; Johns DG
Am J Physiol Heart Circ Physiol; 2010 Jan; 298(1):H251-8. PubMed ID: 19915177
[TBL] [Abstract][Full Text] [Related]
14. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.
Tomlinson JA; Caplin B; Boruc O; Bruce-Cobbold C; Cutillas P; Dormann D; Faull P; Grossman RC; Khadayate S; Mas VR; Nitsch DD; Wang Z; Norman JT; Wilcox CS; Wheeler DC; Leiper J
J Am Soc Nephrol; 2015 Dec; 26(12):3045-59. PubMed ID: 25855779
[TBL] [Abstract][Full Text] [Related]
15. Repetitive ischemia increases myocardial dimethylarginine dimethylaminohydrolase 1 expression.
Zhang P; Fassett JT; Zhu G; Li J; Hu X; Xu X; Chen Y; Bache RJ
Vasc Med; 2017 Jun; 22(3):179-188. PubMed ID: 28145161
[TBL] [Abstract][Full Text] [Related]
16. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes.
Abhary S; Burdon KP; Kuot A; Javadiyan S; Whiting MJ; Kasmeridis N; Petrovsky N; Craig JE
PLoS One; 2010 Mar; 5(3):e9462. PubMed ID: 20209122
[TBL] [Abstract][Full Text] [Related]
17. Correlations of DDAH1 transcript variants with human endothelial asymmetric dimethylarginine metabolizing activity.
Sun T; Zhou JP; Kuang DB; Li MP; Xiong Y; Tang J; Xia J; Bai YP; Yang GP; Li YJ; Chen XP
Am J Hypertens; 2013 Dec; 26(12):1437-44. PubMed ID: 23864585
[TBL] [Abstract][Full Text] [Related]
18. ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Rodionov RN; Heinrich A; Brilloff S; Jarzebska N; Martens-Lobenhoffer J; Bode-Böger SM; Todorov VT; Hugo CPM; Weiss N; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():319-325. PubMed ID: 29096857
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.
Rodionov RN; Dayoub H; Lynch CM; Wilson KM; Stevens JW; Murry DJ; Kimoto M; Arning E; Bottiglieri T; Cooke JP; Baumbach GL; Faraci FM; Lentz SR
Circ Res; 2010 Feb; 106(3):551-8. PubMed ID: 20019334
[TBL] [Abstract][Full Text] [Related]
20. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
